The embattled blood-testing company Theranos on Wednesday night announced a major retrenchment, saying it will shut down its clinical labs and blood collection sites.
Theranos's new plan: To devote its “undivided attention” to developing a new technology, dubbed the miniLab, which is intended to condense the process of running blood tests normally done with several large machines into a single tabletop platform. The technology could be sold to hospitals and doctor's offices, a pivot from Theranos's previous consumer-focused tests.
